166 related articles for article (PubMed ID: 31844925)
1. Insights on the Formulation of Recombinant Proteins.
Ribeiro R; Abreu TR; Silva AC; Gonçalves J; Moreira JN
Adv Biochem Eng Biotechnol; 2020; 171():23-54. PubMed ID: 31844925
[TBL] [Abstract][Full Text] [Related]
2. Intermolecular interactions in highly concentrated formulations of recombinant therapeutic proteins.
Baek Y; Zydney AL
Curr Opin Biotechnol; 2018 Oct; 53():59-64. PubMed ID: 29278833
[TBL] [Abstract][Full Text] [Related]
3. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
[TBL] [Abstract][Full Text] [Related]
4. [Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?].
Goupille P
Rev Med Interne; 2016 May; 37(5):343-9. PubMed ID: 26526777
[TBL] [Abstract][Full Text] [Related]
5. Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies.
Samra HS; He F
Mol Pharm; 2012 Apr; 9(4):696-707. PubMed ID: 22263524
[TBL] [Abstract][Full Text] [Related]
6. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.
Mandal A; Pal D; Agrahari V; Trinh HM; Joseph M; Mitra AK
Adv Drug Deliv Rev; 2018 Feb; 126():67-95. PubMed ID: 29339145
[TBL] [Abstract][Full Text] [Related]
7. Ionic-liquid-based approaches to improve biopharmaceuticals downstream processing and formulation.
Almeida C; Pedro AQ; Tavares APM; Neves MC; Freire MG
Front Bioeng Biotechnol; 2023; 11():1037436. PubMed ID: 36824351
[TBL] [Abstract][Full Text] [Related]
8. The Rebif new formulation story: it's not trials and error.
Jaber A; Driebergen R; Giovannoni G; Schellekens H; Simsarian J; Antonelli M
Drugs R D; 2007; 8(6):335-48. PubMed ID: 17963425
[TBL] [Abstract][Full Text] [Related]
9. The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.
Gourbatsi E; Povey JF; Smales CM
Biotechnol Lett; 2018 Jan; 40(1):33-46. PubMed ID: 28939995
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
11. From cell factories to patients: Stability challenges in biopharmaceuticals manufacturing and administration with mitigation strategies.
Elsayed A; Jaber N; Al-Remawi M; Abu-Salah K
Int J Pharm; 2023 Oct; 645():123360. PubMed ID: 37657507
[TBL] [Abstract][Full Text] [Related]
12. Structural characterization of recombinant therapeutic proteins by circular dichroism.
Bertucci C; Pistolozzi M; De Simone A
Curr Pharm Biotechnol; 2011 Oct; 12(10):1508-16. PubMed ID: 21542799
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
14. Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.
Razinkov VI; Treuheit MJ; Becker GW
J Biomol Screen; 2015 Apr; 20(4):468-83. PubMed ID: 25576149
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of therapeutic proteins: clinical implications and future prospects.
Schellekens H
Clin Ther; 2002 Nov; 24(11):1720-40; discussion 1719. PubMed ID: 12501870
[TBL] [Abstract][Full Text] [Related]
16. Formulation and stability of cytokine therapeutics.
Lipiäinen T; Peltoniemi M; Sarkhel S; Yrjönen T; Vuorela H; Urtti A; Juppo A
J Pharm Sci; 2015 Feb; 104(2):307-26. PubMed ID: 25492409
[TBL] [Abstract][Full Text] [Related]
17. Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies.
Banks DD; Latypov RF; Ketchem RR; Woodard J; Scavezze JL; Siska CC; Razinkov VI
J Pharm Sci; 2012 Aug; 101(8):2720-32. PubMed ID: 22648863
[TBL] [Abstract][Full Text] [Related]
18. Viscosity of concentrated therapeutic protein compositions.
Jezek J; Rides M; Derham B; Moore J; Cerasoli E; Simler R; Perez-Ramirez B
Adv Drug Deliv Rev; 2011 Oct; 63(13):1107-17. PubMed ID: 22014592
[TBL] [Abstract][Full Text] [Related]
19. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment.
Wang T; Kumru OS; Yi L; Wang YJ; Zhang J; Kim JH; Joshi SB; Middaugh CR; Volkin DB
J Pharm Sci; 2013 Aug; 102(8):2520-37. PubMed ID: 23824562
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody higher order structure analysis by high throughput protein conformational array.
Song Y; Yu D; Mayani M; Mussa N; Li ZJ
MAbs; 2018 Apr; 10(3):397-405. PubMed ID: 29313446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
